NCT03362983

Brief Summary

Patient with complex comorbidities present a growing challenge for health-care providers, that the current system is poorly designed to handle. Concomitant cardiovascular disease, renal dysfunction and diabetes represent almost half of all patients attending cardiac, kidney and diabetes clinics. Patients with all three of these will be randomized to standard care or to a combined, integrated, person-centered, intensified chronic disease management.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
131

participants targeted

Target at P50-P75 for not_applicable diabetes-mellitus

Timeline
Completed

Started Jan 2016

Longer than P75 for not_applicable diabetes-mellitus

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2016

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

June 14, 2017

Completed
6 months until next milestone

First Posted

Study publicly available on registry

December 5, 2017

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2020

Completed
Last Updated

January 13, 2021

Status Verified

January 1, 2021

Enrollment Period

3.9 years

First QC Date

June 14, 2017

Last Update Submit

January 12, 2021

Conditions

Outcome Measures

Primary Outcomes (3)

  • Disease progression (n=260)

    Combined death or readmission due to heart failure, myocardial infarction, PCI/CABG, end stage renal failure, acute renal failure or TIA / stroke.

    2 years

  • Patient centered outcome measures (n=131)

    Perceived quality of care and patient empowerment assessed by a PROMs (Patient Reported Outcome Measure) questionaire with a sum score.

    1 year

  • Quality-of-care outcome measures (n=131)

    Combined score of achieved target blood pressure, target HbA1C and target LDL.

    1 year

Secondary Outcomes (5)

  • Organ damage (n=131)

    1 year

  • System biology (n=131)

    1 year

  • Health care structure and utilization (n=131)

    1 year.

  • Patient safety (n=131)

    1 year

  • Interdisciplinary learning (n=20)

    1 year

Study Arms (2)

Care HND Intervention

EXPERIMENTAL

Integrated, multidisciplinary, person centered care at HND-centrum.

Other: CareHND

Standard care

NO INTERVENTION

Standard care at separate specialty clinics and primary care as needed.

Interventions

CareHNDOTHER

Multidisciplinary, integrated, person-centered care at the integrated HND-clinic

Care HND Intervention

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • \- Established cardiovascular disease (such as history of myocardial infarction, angina, or heart failure requiring hospitalization, previous stroke or TIA with certain diagnosis, and peripheral vascular disease), as well as:
  • \- Diabetes mellitus type 1 or 2 (treated diabetes, or new onset diabetes according to WHO criteria or HbA1C \> 48, and symptoms, as well as:
  • \- Established kidney disease (eGFR \<60 mL/min/m2 calculated with the CKD-EPI formula, or an average of the CKD -EPI and Cystatin-C eGFR, or borderline GFR but concomitant microalbuminuria, or macroalbuminuria, or kidney transplant).

You may not qualify if:

  • Inability to provide consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

HND centrum, Danderyd University Hospital

Stockholm, Stockholm County, 18261, Sweden

Location

MeSH Terms

Conditions

Diabetes MellitusRenal Insufficiency, ChronicCardiovascular DiseasesChronic Disease

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Jonas Spaak, MD, PhD

    Danderyd University Hospital and Karolinska Institutet

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 14, 2017

First Posted

December 5, 2017

Study Start

January 1, 2016

Primary Completion

December 1, 2019

Study Completion

November 30, 2020

Last Updated

January 13, 2021

Record last verified: 2021-01

Data Sharing

IPD Sharing
Will share

Upon individual application and review as required by Swedish law.

Locations